Introduction
Hypertensive disease complicates approximately 10 per cent of all pregnancies. The level of blood pressure is closely related to foetal well-being and if persistently elevated it is associated with an increase in perinatal mortality and morbidity. There is still confusion amongst clinicians concerning treatment and consequently the disease accounts for significant maternal and foetal mortality and morbidity. Despite the confusion recent reports show that control of hypertension in pregnancy by antihypertensive drugs results in better survival (Michael 1975; Redman et al., 1976; Michael, 1979a; Gallery et al., 1979) .
The choice of the antihypertensive drug is dependent on its efficacy when administered orally and its freedom from foetal and maternal sideeffects. Many antihypertensive drugs are undesirable for use in pregnancy because of side-effects and a poor hypotensive action (Michael, 1980a) .
The value of labetalol (Trandate) in the control of hypertension complicating pregnancy with resulting improved foetal survival has already been established (Michael, 1979a) . At the King Edward Memorial Hospital for Women, Perth, Australia, labetalol has been the drug of choice since 1979 for those patients with hypertensive disease in pregnancy where the foetus is too immature to consider its delivery. This decision was undertaken following clinical trials with the drug (Michael, 1979a) , which showed that adequate reduction in blood pressure prevented any cerebral or cardiac complications of the hypertension and allowed pregnancy to safely continue until foetal maturity was reached. This resulted in a reduced foetal loss from prematurity by preventing premature induction of labour for uncontrolled hypertension in the mother.
The study now reported shows our extended experience with labetalol in 85 pregnancies where hypertension was a complicating factor.
Methods
In a previous study (Michael, 1979a) (Table 2 ). In all patients treatment was commenced in the middle trimester of pregnancy and continued for a minimum of 1 week and up to a maximum of 19 weeks. Once the blood pressure and proteinuria were Effective control of the blood pressure was achieved in all but six patients. Four of these were less than 30 weeks gestation and had developed fulminating pregnancy induced hypertension with rapidly increasing proteinuria.
The average fall in systolic pressure was 34 mm Hg and in the diastolic pressure 28 mm Hg. Of the 54 patients with proteinuria 14 developed increasing proteinuria and required delivery of the foetus because of this. In the remaining 40 patients the proteinuria improved significantly and was either intermittent (11 patients) or disappeared (29 patients). Eclampsia did not occur in any of the patients.
Maternal side-effects
Side-effects of labetalol in the mother did not cause significant problems. Postural hypotension occurred in four patients, scalp tingling in two, and lethargy, headache and generalized rash in one patient. It was not necessary to discontinue the drug because of side-effects. However in one patient with scalp tingling, delivery of the foetus was necessary because of foetal hypoxia. Further tolerance of the drug by this patient may not have been possible, if the pregnancy had continued.
Renal and hepatic function
Elevation of the serum creatinine levels occurred in five patients though this was thought to be a reflection of the severity of the pregnancy induced hypertension rather than the labetalol treatment. The levels returned to normal after delivery of the foetus. Hepatic function remained normal.
Foeto-placental function
Two patients required delivery because of foetal hypoxia at 32 and 34 weeks gestation even though the hypertension was adequately controlled. Both of the infants survived. None of the 20 patients with essential hypertension developed evidence of reduced foeto-placental function. However in the group of patients with pregnancy induced hypertension superimposed on essential hypertension seven of the 12 patients showed a reduction in plasma oestriol estimation below the mean for their respective gestation and in five of these there was reduced foetal growth demonstrated on ultrasound. In those with pregnancy induced hypertension (53 patients) ten patients showed evidence of reduced foetal well-being as indicated by these parameters of foeto-placental function. Twenty-four of the 89 infants born alive showed evidence of being small for gestational age when assessed by the neonatologist at delivery. There was an over representation of this group of infants in those patients with essential hypertension and superimposed pregnancy induced hypertension. The other 65 infants did not show evidence of intrauterine growth retardation when examined.
The six patients who developed progressive disease despite therapy required delivery because of increasing maternal blood pressure. Four of these infants did not survive. Two died in the neonatal period from pulmonary complications and two infants, both weighing less than 1000 g, were stillborn.
Foetal pulmonary maturity
Labetalol seemed to exert a beneficial effect on the development of foetal pulmonary maturity. In the early part of the trial this assessment was made by estimating the lecithin-sphyngomyelin ratio in the amniotic fluid. Later in the investigation, aminocentesis for the detection of lung maturity was only performed if indicated clinically. Eleven of the infants developed respiratory distress syndrome (RDS) and of these four died in the neonatal period (NND) as demonstrated in Table 3 . Five infants developed hyaline membrane disease (HMD) and all but one of these survived. These findings would support the clinical and biochemical impression that foetal pulmonary immaturity is under represented in a group of preterm infants normally associated with a higher incidence of pulmonary hyaline membrane disease.
Method of delivery
Sixty-four infants were delivered by the vaginal route and of these 35 required forceps, two were delivered by the breech and 27 delivered spontaneously. The increased incidence of Caesarean section (32%) reflects the high risk population being treated. Labetalol did not interfere with labour nor complicate Caesarean section. Spontaneous preterm labour did not occur suggesting that myometrial irritability previously described with the use of P-adrenoceptor-blocking agents in pregnancy was not a problem. However, in those patients in whom induction of labour was performed the induction delivery interval was reduced indicating some excitory effect of the drug on the uterine musculature. (This was considered to be an advantage.) Breast milk labetalol Labetalol was recovered from the breast milk collected on the third post-partum day. The concen- tration did not seem to be related to the maternal plasma levels until the higher levels of the drug were reached. Apart from one infant who had hypotension at birth probably as a result of asphyxia rather than labetalol there were no adverse effects in the infants.
Perinatal outcome
The foetal outcome in relation to birth weight is shown in Table 4 . The two stillbirths weighed 720 g and 640 g respectively and occurred as a result of severe fulminating pregnancy induced hypertension. Fourteen of the infants were asphyxiated at birth and all but the infants that did not survive responded quickly to resuscitation. The total perinatal mortality was 6.6%, an excellent outcome considering the severity of the hypertension. By deleting the two previable stillborn infants from the data the corrected perinatal mortality is further reduced to 4.4%. Although previous studies have emphasized the confusion that exists in the management of hypertensive disease in pregnancy, all agree that the highest perinatal mortality (PNM) is associated with those patients who have essential hypertension together with superimposed pregnancy induced hypertension. This current study is no exception. Seventy-five per cent of the neonatal deaths occurred in this group (Table 5 ). The lowest perinatal mortality was associated with treated maternal essential hypertension. This is a reflection of the meticulous antenatal care these patients received throughout pregnancy and that effective early treatment of the essential hypertension prevents the occurrence of pregnancy exacerbation of the blood pressure with its associated increased perinatal mortality and morbidity. None of the infants showed evidence of oculotoxicity or congenital malformations.
Discussion
The results of this expanded study to evaluate labetalol in pregnancy confirm the efficient hypotensive action of the drug together with its freedom from maternal and foetal complications.
In the past an increasing variety of hypotensive drugs have been used in pregnancy. Unlike this study where a single drug was effective other reports indicate the addition of another antihypertensive to control the blood pressure is frequently required. Gallery et al., (1979) found it necessary to add hydrallazine to both treatment regimens of oxprenalol and methyldopa for improved blood pressure control. Multiple drug therapy confuses an already complex condition involving the mother, the foetus, the foeto-placental unit and its perfusion.
The reported effects of antihypertensive therapy on the placental circulation and therefore oxygenation of the foetus are conflicting. Gallery et al (1979) have suggested an improvement with oxprenalol which is reflected in the size of the infants at birth. (Ounsted et al., 1980) . This may be the sensitive period for brain growth (Editorial, Lancet, 1979) . This apparent effect on foetus head growth was not observed where the foetal has been exposed to labetalol although careful evaluation and follow up is continuing.
This expanded study confirms the previous impression that labetalol is a safe and efficient drug for use in the control of hypertensive disease complicating pregnancy. Its rapid absorption when administered orally allows an early effective reduction in blood pressure. The freedom from maternal and foetal side-effects together with the excellent perinatal outcome in a condition usually accompanied by a high maternal and foetal mortality and morbidity confirms its suitability for use during pregnancy. The low incidence of pulmonary hyaline membrane disease and the possibility that it exerts a direct beneficial effect on foetal lung maturation suggests that it is the drug of choice in the treatment of hypertensive disease arising in or complicating pregnancy.
